{"id":"W4383872109","doi":"10.1080/13696998.2023.2234776","title":"Health care resource utilization in 3L + patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib","year":2023,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"EVERSANA (Canada)","funders":"Novartis Portugal","keywords":"Medicine; Bosutinib; Myeloid leukemia; Chronic care; Health care; Chronic disease; Internal medicine; Oncology; Intensive care medicine; Imatinib; Dasatinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001976762,0.0002259886,0.0005965396,0.0002080394,0.0001981432,0.0005430554,0.0002620366,0.000412533,0.001168323],"category_scores_gemma":[0.002281127,0.0001607445,0.0009106449,0.0004461018,0.0002027535,0.0003201673,0.0003731037,0.0004915948,0.00009185338],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005529573,"about_ca_system_score_gemma":0.0004646724,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001761453,"about_ca_topic_score_gemma":0.002549781,"domain_scores_codex":[0.9985025,0.0009128129,0.0001014008,0.0001659025,0.0001216374,0.0001957846],"domain_scores_gemma":[0.9986957,0.0003269457,0.0006823771,0.00005660421,0.0000436754,0.0001946636],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.05945917,0.001192826,0.9107124,0.0002182095,0.001652992,0.00006829543,0.00008558793,0.001002583,0.001013317,0.00007328023,0.0009284074,0.02359295],"study_design_scores_gemma":[0.005209223,0.009160079,0.9821494,0.00005021209,0.0006860075,0.0001429282,0.0001277387,0.001570138,0.0003442101,0.00008087102,0.0004640853,0.00001503998],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9990193,0.0005286696,0.00003096514,0.00005728666,0.000007565753,0.00002023322,0.0002080372,0.000001373621,0.0001265338],"genre_scores_gemma":[0.9994357,0.0001137925,0.00004315413,0.00006125096,0.00001251512,0.00003426803,0.0002470762,5.907425e-7,0.00005155498],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001976762,"threshold_uncertainty_score":0.01045424,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02998438724378213,"score_gpt":0.3263907657694533,"score_spread":0.2964063785256712,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}